Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,001 | 411 | 98.0% |
| Education | $122.09 | 5 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $1,112 | 81 | $0 (2024) |
| Novo Nordisk Inc | $697.67 | 58 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $595.49 | 36 | $0 (2024) |
| Abbott Laboratories | $504.14 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $466.32 | 33 | $0 (2022) |
| Amgen Inc. | $380.81 | 25 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $234.72 | 15 | $0 (2024) |
| Merck Sharp & Dohme LLC | $188.83 | 22 | $0 (2023) |
| Radius Health, Inc. | $181.52 | 10 | $0 (2024) |
| Ascensia Diabetes Care Us Inc. | $162.83 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $792.08 | 43 | Lilly USA, LLC ($144.28) |
| 2023 | $976.06 | 58 | Lilly USA, LLC ($235.28) |
| 2022 | $482.19 | 32 | Lilly USA, LLC ($119.43) |
| 2021 | $190.29 | 10 | Insulet Corporation ($45.62) |
| 2020 | $114.72 | 8 | Novo Nordisk Inc ($23.81) |
| 2019 | $863.51 | 59 | Novo Nordisk Inc ($234.23) |
| 2018 | $1,307 | 98 | Lilly USA, LLC ($224.19) |
| 2017 | $1,397 | 108 | Lilly USA, LLC ($327.16) |
All Payment Transactions
416 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: DIABETES | ||||||
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Cardiology | ||||||
| 12/16/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/02/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/19/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: Diabetes Care | ||||||
| 10/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Cardio-renal | ||||||
| 10/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Diabetes | ||||||
| 09/30/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE 365 SENSOR KIT (RETAIL) (Device) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Diabetes | ||||||
| 09/17/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Diabetes | ||||||
| 08/29/2024 | Amphastar Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.26 | General |
| 08/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Diabetes | ||||||
| 08/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: Diabetes | ||||||
| 07/30/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Diabetes | ||||||
| 07/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE, SYNJARDY | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: DIABETES | ||||||
| 07/16/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/11/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE E3 SENSOR KIT - RETAIL (Device) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Diabetes | ||||||
| 07/02/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Cardiology | ||||||
| 07/01/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/27/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Diabetes | ||||||
| 06/19/2024 | Chiesi USA, Inc. | MYCAPSSA (Drug) | Food and Beverage | Cash or cash equivalent | $14.74 | General |
| Category: ACROMEGALY | ||||||
| 06/11/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE E3 SENSOR KIT - RETAIL (Device) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Diabetes | ||||||
| 06/10/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 979 | 9,020 | $554,509 | $195,062 |
| 2022 | 10 | 921 | 7,903 | $424,501 | $164,771 |
| 2021 | 10 | 989 | 8,172 | $436,259 | $166,341 |
| 2020 | 12 | 1,234 | 8,311 | $477,420 | $163,382 |
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 70 | 7,740 | $325,080 | $140,891 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 183 | 292 | $105,996 | $23,770 | 22.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 203 | 248 | $63,488 | $14,081 | 22.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $27,260 | $5,957 | 21.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 103 | 177 | $4,248 | $1,685 | 39.7% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 48 | 48 | $4,916 | $1,640 | 33.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 37 | 68 | $6,800 | $1,541 | 22.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 27 | $5,400 | $1,540 | 28.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 177 | 224 | $1,568 | $1,537 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 74 | 123 | $5,043 | $1,280 | 25.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $4,710 | $1,142 | 24.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 67 | 6,720 | $282,240 | $113,615 | 40.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 184 | 281 | $65,192 | $23,854 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 217 | 260 | $41,080 | $14,998 | 36.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 43 | 43 | $15,007 | $4,908 | 32.7% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 110 | 192 | $4,608 | $1,842 | 40.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 48 | 48 | $4,320 | $1,646 | 38.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 30 | 57 | $4,446 | $1,384 | 31.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 66 | 109 | $3,815 | $1,162 | 30.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,519 | $823.94 | 32.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 145 | 182 | $1,274 | $538.08 | 42.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 69 | 6,900 | $289,800 | $112,054 | 38.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 289 | 369 | $58,302 | $22,002 | 37.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 151 | 216 | $50,112 | $19,505 | 38.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 46 | 46 | $16,054 | $5,116 | 31.9% |
About Dr. Mohsen Zena, MD
Dr. Mohsen Zena, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2008. The National Provider Identifier (NPI) number assigned to this provider is 1548436033.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohsen Zena, MD has received a total of $6,123 in payments from pharmaceutical and medical device companies, with $792.08 received in 2024. These payments were reported across 416 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($6,001).
As a Medicare-enrolled provider, Zena has provided services to 4,123 Medicare beneficiaries, totaling 33,406 services with total Medicare billing of $689,556. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Omaha, NE
- Active Since 05/05/2008
- Last Updated 07/07/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1548436033
Products in Payments
- FARXIGA (Drug) $454.54
- HUMULIN (Drug) $368.28
- JARDIANCE (Drug) $317.64
- Victoza (Drug) $276.98
- TOUJEO (Drug) $239.11
- MOUNJARO (Drug) $236.76
- Ozempic (Drug) $227.24
- JANUVIA (Drug) $159.95
- Prolia (Biological) $155.34
- TRADJENTA (Drug) $148.72
- TRULICITY (Drug) $137.66
- EVENITY (Biological) $136.55
- Kerendia (Drug) $133.62
- ENTRESTO (Drug) $129.09
- FreeStyle Libre blood glucose Flash Monitoring System (Device) $123.66
- FREESTYLE LIBRE 3 (Device) $120.12
- Tresiba (Drug) $112.72
- SOLIQUA (Drug) $108.66
- Tymlos (Biological) $105.40
- Omnipod (Device) $102.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Omaha
Dr. Marium Ilahi, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $225,172
Mr. Timothy Wahl, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $200,941
Cyrus Desouza, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $112,516
J. Gallagher, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $14,755
Andjela Drincic, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $13,376
Dr. Claire Baker, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $11,019